By
Latest Stories
Don’t miss our hot and upcoming stories
Will Sanofi’s $9.5B Acquisition of Blueprint Redefine the Future of Rare Immunology?
Key Takeaways for Biopharma Executives Strategic Expansion: Sanofi Bets Big on Rare Immunology and US…
Can Bristol Myers Squibb and BioNTech’s $1.5B Bet on Bispecific Antibodies Disrupt PD1-VEGF Cancer Treatment Landscape?
Key Takeaways for Industry Leaders Strategic Shift: BMS Moves Deeper into Bispecific Immuno-OncologyIn a bold…
How GSK-Backed Onc.AI Is Using Deep Learning Radiomics to Disrupt Imaging Biomarkers in Biopharma Trials
Key Highlights: Reinventing RECIST: How Onc.AI’s Serial CTRS is Transforming Imaging BiomarkersOnc.AI is redefining how…
How Massive Bio’s AI is Unlocking Global Oncology Access for 3,800+ Cancer Patients Through ASCO25 Breakthroughs
Key Highlights: Revolutionizing Cancer Care With Multi-Agent AI at ASCO25Massive Bio is presenting its cutting-edge…